CNBX · XBRL financial data
CNBX Pharmaceuticals financial statements, every fiscal year
The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (CNBX's year ends in late August)
| In thousands of dollars | Aug 31, 2020 | Aug 31, 2021 | †Aug 31, 2022 | †Aug 31, 2023 | Aug 31, 2024 | †Aug 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7 | 0 | 30 | 410 | 130 | 0 |
| Research and development | 1,682 | 1,772 | 1,183 | 432 | 195 | 0 |
| General and administrative | 1,308 | 808 | 1,771 | 910 | 518 | 272 |
| Total operating expenses | 3,051 | 2,600 | 2,954 | 1,342 | 713 | 272 |
| Operating income (loss) | (3,043) | (2,600) | (2,954) | (931) | (583) | (272) |
| Interest expense | — | — | — | — | — | 40 |
| Other income (expense) | (4,424) | (594) | 769 | 53 | 23 | 42 |
| Net income (loss) | (7,467) | (3,194) | (3,723) | (3,710) | (695) | (314) |
| Earnings per share, basic USD per share | — | (0.02) | (3.59) | (0.42) | (0.02) | 0.00 |
| Earnings per share, diluted USD per share | — | (0.02) | (3.59) | (0.42) | (0.02) | 0.00 |
| Weighted average shares, basic thousands of shares | — | 138,520 | 1,223 | 8,825 | 30,248 | 90,649 |
| Weighted average shares, diluted thousands of shares | — | 138,520 | 1,223 | 8,825 | 30,248 | 90,649 |
- † Share count changed about 1/118 in the period ending 2022-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 23x in the period ending 2023-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 18x in the period ending 2025-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (CNBX's year ends in late August)
| In thousands of dollars | Aug 31, 2020 | Aug 31, 2021 | †Aug 31, 2022 | †Aug 31, 2023 | Aug 31, 2024 | †Aug 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 778 | 1,386 | 118 | 130 | 26 | 15 |
| Short-term investments | 0 | — | — | — | — | — |
| Prepaid and other current assets | — | — | 81 | 95 | 5 | 3 |
| Total current assets | 930 | 1,591 | 198 | 224 | 31 | 18 |
| Property and equipment, net | 863 | 643 | 437 | 275 | 0 | 0 |
| Total assets | 2,219 | 3,079 | 811 | 499 | 31 | 18 |
| Total current liabilities | 455 | 1,273 | 2,443 | 2,516 | 2,511 | 2,515 |
| Accumulated deficit | (13,631) | (16,826) | (20,549) | (24,259) | (24,954) | (25,268) |
| Total stockholders' equity | 1,765 | 1,806 | (1,632) | (2,017) | (2,480) | (2,496) |
| Total liabilities and equity | 2,219 | 3,079 | 811 | 499 | 31 | 18 |
| Common shares outstanding (cover page) thousands of shares | 135,080 | 148,661 | 1,258 | 28,311 | 31,111 | 553,962 |
- † Share count changed about 1/118 in the period ending 2022-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 23x in the period ending 2023-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 18x in the period ending 2025-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (CNBX's year ends in late August)
| In thousands of dollars | Aug 31, 2020 | Aug 31, 2021 | †Aug 31, 2022 | †Aug 31, 2023 | Aug 31, 2024 | †Aug 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (7,467) | (3,194) | (3,723) | (3,710) | (695) | (314) |
| Stock-based compensation | — | 0 | 729 | 180 | 140 | 0 |
| Net cash from operating activities | (2,775) | (2,493) | (1,679) | (113) | (244) | (171) |
| Net cash from investing activities | 3,287 | 645 | 25 | 25 | 113 | 0 |
| Proceeds from issuing common stock | 0 | — | — | — | — | — |
| Net cash from financing activities | 0 | 2,457 | 390 | 100 | 28 | 160 |
- † Share count changed about 1/118 in the period ending 2022-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 23x in the period ending 2023-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
- † Share count changed about 18x in the period ending 2025-08-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| CNBX Pharmaceuticals | 9.5 | 0 | (48)* | 1.6B | 0.2 quarters | 10-QMay 31, 2026 |
| Bioadaptives | 29 | 5 | (44)* | 196.9M | 0.7 quarters | 10-QJun 30, 2026 |
| Eloxx Pharmaceuticals | 61,960 | not reported | (4,789)* | 4.0M | 12.9 quarters | 10-QJun 30, 2026 |
| NovAccess Global | 21 | 0* | (55)* | 61.7M | 0.4 quarters | 10-KSep 30, 2024 |
| Avenue Therapeutics | 1,942 | 0 | (475)* | 3.3M | 4.1 quarters | 10-QJun 30, 2026 |
| Emmaus Life Sciences | 2,808 | 6,318 | 1,693* | 70.2M | — | 10-QJun 30, 2026 |
| International Stem Cell | 1,089 | 2,675 | 167* | 8.0M | — | 10-QJun 30, 2026 |
| Nutra Pharma | not reported | 34 | (251)* | 7.2B | 0.1 quarters | 10-QJun 30, 2026 |
| Mosaic ImmunoEngineering | 0 | not reported | (0)* | 7.2M | 0.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.